Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats

European Journal of Pharmacology

Volumn 461, Issue 2-3, 2003, Pages 119-128

  Byrnes Blake, Kelly A ^a,d   Laurenzana, Elizabeth M ^a   Carroll, F Ivy ^b   Abraham, Philip ^b   Gentry, W Brooks ^a   Landes, Reid D ^c,e   Owens, S Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d ZYMOGENETICS INC   (United States)

^e IOWA STATE UNIVERSITY   (United States)

Author keywords

Behavior; Drug abuse; Methamphetamine; Monoclonal antibody; Pharmacokinetics

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; METHAMPHETAMINE MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ARTICLE; BINDING SITE; BLOOD LEVEL; BRAIN LEVEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG MECHANISM; FEMALE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

EID: 0037436021     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01313-X     Document Type: Article

References (28)

1. Albertson T.E., Derlet R.W., Van Hoozen B.E. Methamphetamine and the expanding complications of amphetamines. West. J. Med. 170:1999;214-219.
2. Bazin-Redureau M.I., Renard C.B., Scherrmann J.M. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat. J. Pharm. Pharmacol. 49:1997;277-281.
3. Beebe D.K., Walley E. Smokable methamphetamine ('ice'): an old drug in a different form. Am. Fam. Phys. 51:1995;449-453.
4. Cho A.K. Ice: a new dosage form of an old drug. Science. 249:1990;631-634.
5. Cho A.K., Melega W.P., Kuczenski R., Segal D.S., Schmitz D.A. Caudate-putamen dopamine and steroptypy response profiles after intravenous and subcutaneous amphetamine. Synapse. 31:1999;125-133.
6. Cook C.E., Jeffcoat A.R., Hill J.M., Pugh D.E., Patetta P.K., Sadler B.M., White W.R., Perez-Reyes M. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab. Dispos. 21:1993;717-723.
7. Davis M.T., Preston J.F. A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking. Anal. Biochem. 116:1981;402-407.
8. Derlet R.W., Heischober B. Methamphetamine: stimulant of the 1990s? West. J. Med. 153:1990;625-628.
9. Drug Abuse Warning Network Year-End 1998 Emergency Department Data from the Drug Abuse Warning Network. 1999;Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Rockville, MD.
10. Ernst T., Chang L., Leonido-Yee M., Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology. 54:2000;1344-1349.
11. Geyer M.A. Serotonergic functions in arousal and motor activity. Behav. Brain Res. 73:1996;31-35.
12. Hardin J.S., Wessinger W.D., Proksch J.W., Owens S.M. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J. Pharmacol. Exp. Ther. 285:1998;1113-1122.
13. Hardin J.S., Wessinger W.D., Wenger G.R., Proksch J.W., Laurenzana E.M., Owens S.M. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J. Pharmacol. Exp. Ther. 302:2002;119-126.
14. 11C]WIN-35,428. J. Neurosci. 18:1998;8417-8422.
15. Owens S.M., Zorbas M., Lattin D.L., Gunnell M., Polk M. Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. J. Pharmacol. Exp. Ther. 246:1988;472-478.
16. Proksch J.W., Gentry W.B., Owens S.M. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in tats. J. Pharmacol. Exp. Ther. 292:2000;831-837.
17. Rivière G.J., Byrnes K.A., Gentry W.B., Owens S.M. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J. Pharmacol. Exp. Ther. 291:1999;1220-1226.
18. Rivière G.J., Gentry W.B., Owens S.M. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J. Pharmacol. Exp. Ther. 292:2000;1042-1047.
19. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models in amphetamine psychosis. Brain Res. 396:1986;157-198.
20. Rowland M., Tozer T. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. 1995;Williams and Wilkins, Baltimore.
21. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33:1993;639-677.
22. Spiegelberg H.L., Weigle W.O. The immune response to human gamma-G-immunoglobulin in rabbits unresponsive to Fc fragment and H chain protein. J. Immunol. 98:1967;1020-1027.
23. Valentine J.L., Owens S.M. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J. Pharmacol. Exp. Ther. 278:1996;717-724.
24. Valentine J.L., Arnold L.W., Owens S.M. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J. Pharmacol. Exp. Ther. 269:1994;1079-1085.
25. Valentine J.L., Mayersohn M., Wessinger W.D., Arnold L.W., Owens S.M. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J. Pharmacol. Exp. Ther. 278:1996;709-716.
26. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry. 158:2001;377-382.
27. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Miller E.N., Hitzemann R., Ding Y.S., Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21:2001;9414-9418.
28. Williams R.T., Caldwell J., Dring L.G. Comparative metabolism of some amphetamines in various species. Usdin E., Snyder S.H. Frontiers in Catecholamine Research. 1973;927-932 Pergamon, New York, NY.